Search Results - "Essell, J."

OUTREACH: PRELIMINARY SAFETY & EFFICACY RESULTS FROM A PHASE 2 STUDY OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN THE NONUNIVERSITY SETTING by Godwin, J. E., Mattar, B., Maris, M., Bachier, C., Stevens, D. A., Hoda, D., Varela, J. C., Cherry, M., Fanning, S., Essell, J., Yimer, H., Courtright, J., Sharman, J., Trede, N. S., Youssef, M., Lymp, J., Shaughnessy, P.

Get full text

P1455: FIRST‐IN‐HUMAN TRIAL OF CB‐010, A CRISPR‐EDITED ALLOGENEIC ANTI‐CD19 CAR ‐T CELL THERAPY WITH A PD‐1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON‐HODGKIN LYMPHOMA (ANTLER STUDY) by Nastoupil, L. J., O'Brien, S., Holmes, H. E., Dsouza, L., Hart, D., Matsuda, E., Satterfield‐Ledbetter, T., Skoble, J., Garner, E., Bryan, M., Kanner, S., Li, E., Thomas, C. T., Essell, J.

Get full text

S258: LISOCABTAGENE MARALEUCEL (LISO‐CEL) AS SECOND‐LINE THERAPY FOR R/R LARGE B‐CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PRIMARY ANALYSIS FROM THE PHASE 2 PILOT STUDY by Sehgal, A., Hoda, D., Riedell, P. A., Ghosh, N., Hamadani, M., Hildebrandt, G. C., Godwin, J. E., Reagan, P., Wagner‐Johnston, N., Essell, J., Nath, R., Solomon, S. R., Champion, R., Licitra, E., Fanning, S., Gupta, N., Dubowy, R., D'Andrea, A., Wang, L., Gordon, L. I.

Get full text

Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment of Patients (Pts) with Multiple Myeloma (MM) Who Are Not Candidates for High Dose Chemotherapy by Berdeja, J.G, Bauer, T, Essell, J, Arrowsmith, E, Chu, L, Acs, P, Boccia, R.V, Flinn, I

Get full text

Ursodiol prophylaxis against Hepatic complications of allogeneic bone marrow transplantation: A randomized, double-blind, placebo-controlled trial by ESSELL, J. H, SCHROEDER, M. T, HARMAN, G. S, HALVORSON, R, LEW, V, CALLANDER, N, SNYDER, M, LEWIS, S. K, ALLERTON, J. P, THOMPSON, J. M

“…Hepatic complications are a major cause of illness and death after bone marrow transplantation. To confirm the results of a pilot study that indicated that…”
Get full text

Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass by Essell, J H, Martin, T J, Salinas, J, Thompson, J M, Smith, V C

“…This prospective study of 36 adult patients undergoing cardiopulmonary bypass (CPB) was conducted to determine the utility of thromboelastography (TEG) versus…”
Get more information

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens by Niesvizky, Ruben, Flinn, Ian W, Rifkin, Robert, Gabrail, Nashat, Charu, Veena, Clowney, Billy, Essell, James, Gaffar, Yousuf, Warr, Thomas, Neuwirth, Rachel, Zhu, Yanyan, Elliott, Jennifer, Esseltine, Dixie-Lee, Niculescu, Liviu, Reeves, James

“…The US community-based, phase IIIB UPFRONT trial was designed to compare three frontline bortezomib-based regimens in transplantation-ineligible patients with…”
Get full text

Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory NHL: A phase IB/II study by Phillips, T., Brunvand, M., Chen, A. I., Essell, J., Chiappella, A., Diefenbach, C., Cheng, J., Ramies, D., Hirata, J., Morschhauser, Franck, Flinn, I. W.

Get full text

Oral cavity complications of bone marrow transplantation by Eisen, D, Essell, J, Broun, E R

“…Bone marrow transplantation, once regarded as experimental, has evolved into a standard treatment for a variety of malignancies. Considerable advances have…”
Get more information

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma by Berdeja, Jesus G, Hart, Lowell L, Mace, Joseph R, Arrowsmith, Edward R, Essell, James H, Owera, Rami S, Hainsworth, John D, Flinn, Ian W

“…The purpose of this study was to assess the safety and efficacy of the combination of panobinostat and carfilzomib in patients with relapsed/refractory…”
Get full text

Marked Increase in Veno-Occlusive Disease of the Liver Associated With Methotrexate Use for Graft-Versus-Host Disease Prophylaxis in Patients Receiving Busulfan/Cyclophosphamide by Essell, James H., Thompson, James M., Harman, Glenn S., Halvorson, Ronald D., Snyder, Michael J., Johnson, Robert A., Rubinsak, James R.

“…The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone…”
Get full text

Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients by Essell, J H, Thompson, J M, Harman, G S, Halvorson, R D, Snyder, M J, Callander, N S, Clement, D J

“…Ursodiol is a hydrophilic, non-hepatotoxic bile salt indicated for the medical treatment of cholesterol gallstones. This pilot study explored the use of…”
Get more information

Diversity of organ site involvement among malignant lymphomas of mucosa-associated tissues by Pelstring, R J, Essell, J H, Kurtin, P J, Cohen, A R, Banks, P M

“…Fifteen cases of low-grade B-cell lymphoma involving unusual extranodal sites have been studied in comparison to cases reported or observed arising in typical…”
Get more information

Abciximab-associated profound thrombocytopenia : Therapy with immunoglobulin and platelet transfusion by KEREIAKES, D. J, ESSELL, J. H, ABBOTTSMITH, C. W, BRODERICK, T. M, RUNYON, J. P

“…First-time abciximab administration was associated with acute profound thrombocytopenia in 4 of 575 consecutive patients. Therapy with platelet transfusion,…”
Get full text

PS1533 KD025–208: A PHASE 2A TRIAL OF KD025 FOR PATIENTS WITH CHRONIC GRAFT‐VERSUS‐HOST DISEASE (CGVHD) – UPDATED SAFETY AND EFFICACY by Salhotra, A., Zoghi, B., Essell, J., Bachier, C.R., Weisdorf, D.J., Lazaryan, A., Green, L.S., Schueller, O., Huang, L., Yang, Z., Eiznhamer, D., Aggarwal, S.K., Blazar, B.R., Lee, S.J., Jagasia, M.

“…Background: KD025 is an inhibitor of ROCK2 in a pivotal clinical trial for chronic graft‐versus‐host disease (cGVHD). Inhibition of ROCK2 downregulates TH17…”
Get full text

Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study by Snyder, M J, Johnson, D B, Daly, M B, Giguere, J K, Harman, G H, Harden, E A, Johnson, R A, Leff, R S, Mercier, R J, Messerschmidt, G L

“…The purpose of this study was to define the dose-limiting non-hematologic toxicity of carmustine, Ara C, cyclophosphamide and etoposide (BACE). Between October…”
Get more information

Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy by EISEN, D, ESSELL, J, BROUN, E. R, SIGMUND, D, DEVOE, M

“…Oral acyclovir has been demonstrated to prevent reactivation of herpes simplex virus (HSV) infections when administered prophylactically to autologous bone…”
Get full text

Chemotherapy administration associated errors before and after use of electronic order entry and decision support by Kirlin, D. L., DeVoe, M. G., Brennan, L. V., Drosick, D. R., Essell, J. H., Hawley, D. K., Bowman, R. M., Heaton, D., Neuss, M. N., Guo, J. J.

“…Abstract only 19528 Chemotherapy Administration Associated Errors Before and After Use of Electronic Order Entry and Decision Support Background: Chemotherapy…”
Get full text

Drug-induced thrombocytopenia presenting with isolated oral lesions: report of two cases by Eisen, D, Essell, J

“…Patients with platelet-mediated bleeding disorders often present with clinical manifestations of bruising and bleeding. Although these changes are detected…”
Get more information

177Outcome of patients treated with high dose melphalan with or without TBI followed by CD34 selected stem cell rescue using the Baxter Isolex 3001 by Broun, E.R., Sigmund, D., Essell, J., Tierney, C.

Get full text